Flexion Therapeutics Inc. (NASDAQ:FLXN) Director Samuel D. Colella acquired 33,333 shares of the business’s stock in a transaction on Monday, November 21st. The shares were purchased at an average price of $18.00 per share, with a total value of $599,994.00. Following the transaction, the director now owns 25,504 shares in the company, valued at approximately $459,072. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Flexion Therapeutics Inc. (NASDAQ:FLXN) traded up 3.05% during midday trading on Wednesday, hitting $18.56. 147,223 shares of the company’s stock traded hands. The company’s market capitalization is $510.90 million. Flexion Therapeutics Inc. has a 52 week low of $7.56 and a 52 week high of $23.57. The company has a 50 day moving average of $19.37 and a 200-day moving average of $16.56.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Monday, November 7th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.02. Equities research analysts predict that Flexion Therapeutics Inc. will post ($2.76) earnings per share for the current year.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Several large investors have recently modified their holdings of FLXN. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Flexion Therapeutics by 27.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 4,307,870 shares of the specialty pharmaceutical company’s stock valued at $64,467,000 after buying an additional 927,625 shares during the period. Peregrine Capital Management LLC acquired a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $14,126,000. TPG Group Holdings SBS Advisors Inc. acquired a new stake in shares of Flexion Therapeutics during the second quarter valued at approximately $10,689,000. Bank of New York Mellon Corp boosted its stake in shares of Flexion Therapeutics by 64.3% in the second quarter. Bank of New York Mellon Corp now owns 1,594,026 shares of the specialty pharmaceutical company’s stock valued at $23,855,000 after buying an additional 623,763 shares during the period. Finally, BlackRock Fund Advisors boosted its stake in shares of Flexion Therapeutics by 33.5% in the third quarter. BlackRock Fund Advisors now owns 1,003,825 shares of the specialty pharmaceutical company’s stock valued at $19,615,000 after buying an additional 251,804 shares during the period. Institutional investors and hedge funds own 68.99% of the company’s stock.

A number of equities analysts have commented on FLXN shares. Lake Street Capital restated a “buy” rating and set a $38.00 price objective on shares of Flexion Therapeutics in a research report on Tuesday, September 6th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a research report on Wednesday, November 2nd. Finally, BCS cut their price objective on shares of Flexion Therapeutics from $0.65 to $0.02 in a research report on Tuesday, November 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Flexion Therapeutics has a consensus rating of “Buy” and a consensus target price of $28.28.

TRADEMARK VIOLATION NOTICE: “Flexion Therapeutics Inc. (FLXN) Director Samuel D. Colella Buys 33,333 Shares” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and reposted in violation of United States and international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/23/flexion-therapeutics-inc-flxn-director-samuel-d-colella-buys-33333-shares.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

5 Day Chart for NASDAQ:FLXN

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.